Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By Freedom Bunker
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

It’s All About Mag 7 Earnings: Without Them S&P Profit Growth Is Negative

% of readers think this story is Fact. Add your two cents.


It’s All About Mag 7 Earnings: Without Them S&P Profit Growth Is Negative

After what has been a boring start to the week, where the biggest event so far was yesterday’s start of corporate buyback frontrunning (as we first detailed and bottom ticked the market, which is now 100 points higher since our comment), investors are bracing for some serious fireworks after the close with Tesla, which coming into today was down a record-matching 7 consecutive days although today may finally be a green close, set to report after the close and launch the Mag 7 earnings train in motion.

And while we detailed what one can expect from Tesla earlier, here is another look at the all-important Mag 7 earnings parade, which starts today and continues tomorrow with META and Thursday with GOOGL and MSFT, amid an earnings bonanza that includes 180 companies or 40% of the S&P500 by market value.

To say that these matter a lot is an understatement: as shown in the chart below, profits for the Magnificent Seven are forecast to rise 38% in the first quarter from a year ago (only TSLA is expected to show a drop in profit), dwarfing the overall S&P 500’s puny 2.4% anticipated year-over-year earnings growth. That said, excluding Nvidia net income growth for the Mag7s falls to just 23%.

Some more detail comes from DataTrek’s Nick Colas who writes that without the 5 Big Tech names, S&P 500 earnings would be down 6.0% in Q1 rather than the consensus estimate of +0.5 pct growth: “AMZN, GOOG, META, MSFT and NVDA are the difference.” Colas also notes that the S&P 495” are expected to turn the corner later this year, supporting current equity market valuations.

They better: while the Mag. 7 (really NVDA) are reporting blowing earnings growth, they are slowing down to +38% YoY this quarter vs. +63% in 4Q 2023, with all seven companies expected to see either decelerating EPS growth or an EPS decline YoY.

And, as noted above, the other 493′s earnings are expected to further decline to -6% YoY (vs. flat in 4Q), but 1Q is expected to be the trough (consensus +8% YoY in 2Q). According to BofA’s latest earnings tracker (full note available to pro subs in the usual place), 25% of stocks are also expected to see positive and accelerating EPS growth in 1Q. Bottom line: the growth differential between the Mag. 7 and the other 493 is expected to close by 4Q…

… which should lead to a rotation out of Tech and into more Value-oriented stocks.

And so, with Mag7 earnings about to start, almost all the Magnificent 7 stocks still sitting below their price levels from two weeks ago despite Monday’s rebound, BofA’s derivatives team notes that further upside driven by favorable earnings results in these stocks is certainly possible. To position for this upside with asymmetry, the bank likes using options-based structures rather than buying the stocks outright.

Interestingly, the BofA derivatives desk points out that compared to historical earnings day reactions, options markets are currently pricing in a smaller earnings-driven move for the upcoming season for five out of seven of the megacap tech stocks…

…  which also motivates buying optionality to position for a rally.

While the simplest expression of this would be to buy call options on each of these stocks, BofA also likes funding the calls by selling OTM put spreads of the same tenor. Specifically, the bank is considering partially funding 50-delta calls (expiring on the Friday of the week that the stock releases earnings) with 40-delta/20-delta put spreads of the same tenor.  While this introduces some degree of downside risk, the structure remains limited risk while offering a historically attractive discount vs buying an outright 50D call for these seven stocks.

Finally going back to Tesla, Goldman cautions that while there is clearly skepticism on both TSLA and the EV market as a whole, with deliveries already announced for 1Q (stock was down 5% on this and another -14% additionally since), much of this has been priced in with short interest is at 3-year highs. Goldman thinks the key focus for investors will be

  1. Can they grow volumes in 2024? We think investors were at +10-15% y/y to start the year and are GIR is now in the 1-2% range and
  2. What are gross margins and how low do they need to go? Consensus looks to be 15.8% (ex-credits) tonight and bogey seems to be below 15% for the quarter.

More in the full BofA note available to pro subs.

Tyler Durden Tue, 04/23/2024 – 15:25

Read More…


Source: https://freedombunker.com/2024/04/23/its-all-about-mag-7-earnings-without-them-sp-profit-growth-is-negative/


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.


LION'S MANE PRODUCT


Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules


Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.



Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.


Report abuse

    Comments

    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    MOST RECENT
    Load more ...

    SignUp

    Login

    Newsletter

    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.